Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Friday, November 15th.

Aethlon Medical Stock Performance

NASDAQ:AEMD opened at $0.41 on Monday. The company has a fifty day moving average of $0.40 and a two-hundred day moving average of $0.42. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.35. The stock has a market capitalization of $5.75 million, a PE ratio of -0.15 and a beta of 1.74.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.